Menarini Group signs licensing deal with Insilico for promising cancer treatment

[News]

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

More... (https://www.news-medical.net/news/20250110/Menarini-Group-signs-licensing-deal-with-Insilico-for-promising-cancer-treatment.aspx)